Labopharm Inc. Posts Wider Loss, Revenue Rises

TORONTO, Nov 11 (Reuters) - Canada’s Labopharm Inc (DDS.TO), which specializes in controlled-release drugs, posted on Thursday a wider net loss as higher sales and marketing expenses offset improved revenue.

MORE ON THIS TOPIC